News >

Immunotherapy Shakes Up Stage IV Squamous NSCLC Treatment

Kristi Rosa
Published: Friday, Nov 22, 2019

Christine Bestvina, MD

Christine Bestvina, MD

The emergence of immunotherapy in the treatment paradigm for stage IV squamous non–small cell lung cancer (NSCLC) has led to prolonged survival benefit in select patients, said Christine Bestvina, MD, and PD-L1 expression can be used to determine whether these agents should be given alone or in combination with chemotherapy. However, questions remain.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication